Addex drug candidate effective
Andhra Pradesh ~ India ~ International ~ City ~ Entertainment ~ Business ~ Sports ~ Technology ~ Health ~ Features
Ratan Tata ~ Pranab Mukherjee ~ Forex Rates ~ Bullion Rates ~ RBI ~ SEBI ~ Stock Markets
Home / Business News / 2010 / September 2010 / September 2, 2010
Addex drug-candidate effective in Alzheimer's disease model
RSS / Print / Comments


Reportlinker Adds Global Milk Industry

Cellular defect that leads to cancer discovered

Why family history ups Alzheimers risk - especially from the maternal side

More on Protein


Obese police officers of South Africa asked to to shape up or ship out

Addex Awarded Michael J. Fox Foundation Grant for ADX48621 to treat Levodopa-Induced Dyskinesia in Parkinson's Disease

Addex drug-candidate effective in Alzheimer's disease model

More on GlaxoSmithKline

Alzheimer's Disease

A faster way to look for drugs that regenerate nerve cells

Paralysed patient becomes world's first to get stem cell therapy

Experimental vaccine against Alzheimer's disease created

More on Alzheimer's Disease

Top News

144 Section in Hyderabad ahead of Ayodhya verdict

18 killed, several injured as bus falls into river in Bulandshahr

Pak's flawed Afghan policy of support to terror groups will bite back hard: Editorial

Ajay Devgan prays for success of his film in Ajmer

Pranab Mukherjee seeks more financial sector reforms

Australia asks CWG organizers for better treatment at closing ceremony

Study to find whether leptin helps type 1 diabetic patients

New study confirms smoking, cancer link (reissue)

Addex drug-candidate effective in Alzheimer's disease model

Addex Pharmaceuticals / Addex drug-candidate effective in Alzheimer'sdisease model processed and transmitted by Hugin AS. The issuer is solelyresponsible for the content of this announcement

GENEVA, SWITZERLAND -- (Marketwire) -- 09/02/10 --

Addex Pharmaceuticals / Addex drug-candidate effective in Alzheimer'sdisease model processed and transmitted by Hugin AS. The issuer is solelyresponsible for the content of this announcement.

Allosteric modulation company AddexPharmaceuticals Ltd (SWISS: ADXN) announced today that it has observedefficacy ina model of Alzheimer's disease using a recently discovered orally-availabledrug-candidate. The proprietary molecule specifically inhibits areceptorsubtype called the metabotropic glutamate receptor 2 (mGluR2) vianegativeallosteric modulation (NAM). An Addex mGluR2 NAM is scheduled to enterPhase Iclinical testing in healthy volunteers during 2011.

"Specifically targeting the signaling of the neurotransmitter glutamateusingmGluR2 NAM is one of the most promising avenues of research fortreatingcognitive symptoms of Alzheimer's disease," said Vincent Mutel, CEO ofAddex."We are excited that our mGluR2 NAM has shown that it can improve memory inthispathophysiologically relevant model. Although we are years away fromknowing ifthe drug will work in humans, recently published academic research suggeststhatmGluR2 inhibition also may slow the progression of this devastatingdisease."

The Addex mGluR2 NAM was tested in a model that mimics aspectsof thepathophysiology and cognitive impairment, including progressivememoryimpairment, observed in human Alzheimer's disease. In the preclinicalstudy, themGluR2 NAM dose-dependently reversed memory deficit exhibited after beta-amyloidadministration. Working memory impairment was measured using the novelobjectrecognition (NOR) test. The statistically significant effect was similarto theactive comparator used in the same experiment, donepezil (Aricept),thebenchmark marketed drug currently used to treat symptoms of Alzheimer'sdisease.Furthermore, the mGluR2 NAM did not change locomotor activitycompared tovehicle.

Alzheimer's disease is a progressive brain disease affecting up to 5.3millionAmericans and the seventh-leading cause of death in the UnitedStates. Itdestroys brain cells causing memory loss and problems withthinking andbehavior. There is no cure and marketed drugs offer temporary moderateefficacy.

mGluR2 is a G-protein coupled receptor (GPCR) that is expressed in thebrain onpresynaptic nerve terminals where it slows glutamate release. Research hasshownthat too much signaling by mGluR2 may negatively impact the survival ofbraincells involved in memory, contributing to the cause of Alzheimer'sdisease.Additional research, including the data discussed above, suggests thatmGluR2inhibition can improve working memory, even in cases where memoryalready hasbeen impaired.

Addex Pharmaceuticals ( discovers and developsallostericmodulators for human health and is focused on validated therapeutictargets fordiseases of the central nervous system, metabolic disorders andinflammation.Subject to regulatory approvals, Phase II clinical trials are expected tostartsoon in four indications for two lead products: ADX48621, an mGluR5negativeallosteric modulator (NAM), in dystonia and Parkinson's disease levodopa-induceddyskinesia (PD-LID); and ADX71149, an mGluR2 positive allostericmodulator(PAM), in schizophrenia and anxiety. A third product, ADX71943, GABA-BreceptorPAM with potential for chronic pain, is scheduled to enter Phase Itesting in2011. In addition, Merck & Co., Inc. has licensed rights to twopreclinicalproducts: mGluR4 PAM for Parkinson's disease and mGluR5 PAM forschizophrenia.Additional preclinical discovery stage programs include: GLP1R PAM,IL1R1 NAMand TNFR1 NAM. Roche Venture Fund and SR-One, corporate venturearm ofGlaxoSmithKline, are investors in Addex.

Chris Maggos
Investor Relations & Communications
Addex Pharmaceuticals
+41 22 884 15 11

Disclaimer: The foregoing release may contain forward-looking statementsthatcan be identified by terminology such as "not approvable","continue","believes", "believe", "will", "remained open to exploring", "would","could",or similar expressions, or by express or implied discussions regardingAddexPharmaceuticals Ltd, its business, the potential approval of itsproducts byregulatory authorities, or regarding potential future revenues fromsuchproducts. Such forward-looking statements reflect the current views ofAddexPharmaceuticals Ltd regarding future events, future economicperformance orprospects, and, by their very nature, involve inherent risks anduncertainties,both general and specific, whether known or unknown, and/or any otherfactorthat may materially differ from the plans, objectives, expectations,estimatesand intentions expressed or implied in such forward-looking statements.Such mayin particular cause actual results with allosteric modulators of mGluR2,mGluR4,mGluR5, mGluR7 or other therapeutic targets to be materially differentfrom anyfuture results, performance or achievements expressed or implied bysuchstatements. There can be no guarantee that allosteric modulators ofmGluR2,mGluR4, mGluR5, mGluR7 will be approved for sale in any market orby anyregulatory authority. Nor can there be any guarantee that allostericmodulatorsof mGluR2, mGluR4, mGluR5, mGluR7 or other therapeutic targets willachieve anyparticular levels of revenue (if any) in the future. In particular,management'sexpectations regarding allosteric modulators of mGluR2, mGluR4, mGluR5,mGluR7or other therapeutic targets could be affected by, among otherthings,unexpected actions by our partners, unexpected regulatory actions ordelays orgovernment regulation generally; unexpected clinical trial results,includingunexpected new clinical data and unexpected additional analysis ofexistingclinical data; competition in general; government, industry and generalpublicpricing pressures; the company's ability to obtain or maintain patent orotherproprietary intellectual property protection. Should one or more of theserisksor uncertainties materialize, or should underlying assumptions proveincorrect,actual results may vary materially from those anticipated, believed,estimatedor expected. Addex Pharmaceuticals Ltd is providing the information inthispress release as of this date and does not undertake any obligation toupdateany forward-looking statements contained in this press release as aresult ofnew information, future events or otherwise, except as may berequired byapplicable laws.


This announcement is distributed by Thomson Reuters on behalf ofThomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright andother applicable laws; and

(ii) they are solely responsible for the content, accuracy andoriginality of the information contained therein.

Source: Addex Pharmaceuticals via Thomson Reuters ONE



Link to this page

Suggested pages for your additional reading on Facebook

© 2000-2017 All Rights Reserved and are of their respective owners.
Disclaimer, Terms of Service & Privacy Policy | Contact Us